Avadel Pharmaceuticals PLC (AVDL)

12.780 +0.230 (+1.83%)
Closed USD Disclaimer
12.990 +0.210 (+1.643%)

Avadel Pharmaceuticals PLC Company Profile

Equity Type
Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company's lead product candidate, FT218, is an investigational once-nightly, extended-release formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. Its drug delivery technologies include Micropump, LiquiTime, and Medusa. Its Micropump drug-delivery technology allows for the controlled delivery of small molecule drugs taken orally, which improves dosing compliance, reduces toxicity and improves patient compliance. Its LiquiTime technology allows for development of modified release oral products in a liquid suspension formulation, which makes such formulations particularly well suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of modified-release-injectable dosage formulations of drugs, such as peptides, polypeptides, proteins, and small molecules.
Contact Information
Dublin,2 Ireland
353 1 901 5201
Top Executives
Patrick Couvreur 0 0000 Member of Scientific Advisory Board
Catherine Bréchignac 75 2011 Chairman of Scientific Advisory Board
Peter J. Thornton 57 2017 Independent Director
Linda S. Palczuk 60 2018 Independent Director
Gregory J. Divis 55 2017 CEO & Director
Jean-Marie Pierre Lehn 83 2005 Member of Scientific Advisory Board
Christian Trepo 0 2005 Member of Scientific Advisory Board
Geoffrey M. Glass 48 2018 Independent Non-Executive Chairman of the Board
Mark A. McCamish 69 2019 Independent Director
Eric J. Ende 53 2018 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.